Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

S1 2018 Earnings Call
Company Participants
FINAL

Denis Kessler, Chairman and Chief Executive Officer
Francois de Varenne , Chief Executive Officer
Ian Kelly, Head of Investor Relations
Laurent Rousseau, Deputy Chief Executive Officer
Mark Kociancic, Chief Financial Officer
Paolo De Martin, Chief Executive Officer
Unidentified Speaker
Victor Peignet, Chief Executive Officer

Other Participants
Andrew Ritchie , Analyst
Frank Kopfinger, Analyst
Guilhem Horvath, Analyst
Iain Pearce , Analyst
Ivan Bokhmat, Analyst

Bloomberg Transcript

Jonny Irwin, Analyst
Kamran Hossain, Analyst
Paris Hadjiantonis , Analyst
Sami Taipalus , Analyst
Vikram Gandhi, Analyst
Vinit Malhotra, Analyst

Presentation
Operator
Good day, ladies and gentlemen, and welcome to the SCOR Group Q2 2018 Results Call.
Today's conference is being recorded. There will be an opportunity to ask questions after
the presentation. (Operator Instructions).
At this time, I would like to hand the call over to Mr. Ian Kelly, Head of Investor Relations.
Please go ahead, sir.

Ian Kelly

{BIO 19976646 <GO>}

Page 1 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

Good morning, everybody, and welcome to the SCOR Group 2018 First Half Results Call. I
please ask you to consider the disclaimer on page two of the presentation, which
indicates that the financial results for the first half of 2018 in subject to the completion of a
limited review by SCOR's independent auditors.

FINAL

With this, I would like to give the floor to Denis Kessler, Chairman and CEO of the SCOR
Group, who is joined on this call by the entire company [ph]. Thank you.

Denis Kessler

{BIO 1498477 <GO>}

Thank you, Ian, and good morning, everyone. As you might have seen, SCOR delivers
strong results in the first half of this year. And we do outperform profitability and solvency
target. So we continue to deliver disciplined and profitable endogenous growth with both
the Life and P&C divisions expanding the footprints in targeted territories and business
lines, and delivering a robust technical profitability.

Bloomberg Transcript

Gross written premiums totaled more than EUR7.5 billion in the first half of 2018, up 8.2%
at constant exchange rates compared to the same period last year. This growth comes
from the excellent performance of two business engines. SCOR Global P&C, first,
delivered successful renewals in June-July, in line with January and April renewals with
continued price and volume improvements and higher expected profitability.
SCOR Global P&C pursues expansions of its franchise in the US, the largest P&C market in
the world, where we have a unique position to gain market share. In addition, we continue
to develop the cost benefits between our Lloyd's Syndicate, Channel 2015 and SCOR
Business Solutions, who offer our clients a comprehensive offering on the London market.
Again, SCOR Global Life is also pursuing the expansion of its franchise, in particular, in Asia
Pacific and in Financial Solutions, again, in line with Vision in Action. In addition, SCOR
Global Life launched SCOR Life & Health Ventures and announced the venture's first
strategic investment.
The SCOR delivers an excellent technical profitability in the first half of 2018. The P&C
combined ratio stands at 91.4%. And the Life technical margin at 6.9%, whilst return on
invested assets, which was 2.5%. In the first six months of 2018, we have had to face a
issue raised by the Base Erosion and Anti-Abuse Tax provision of the US tax reform. We
have managed it through the implementation of certain changes through operational
structure.
Despite the accounting charge stemming from the implementation of this new
operational structure, which is by the way fully accounted for in the second quarter of
2018, and represents a total expense of EUR62 million. The SCOR Group meet its ROE
target over the first half of 2018, the net income standing at EUR262 million.
If we were to exclude this accounting charge SCOR's net income for the first six months
of 2018 would have reached EUR324 million, corresponding to a return on equity of 10.9%
well above the Vision in Action profitability target. Solvency ratio of the group is strong,
Page 2 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

standing at 221%, at the end of the second quarter, at the end of June, slightly above the
optimal range of the solvency scale following robust capital generation since the 1st of
January.
Finally, the SCOR continues to execute its EUR200 million share buyback program as
planned with EUR67 million of shares bought back to date. Thus one-third of the program
has been executed and completion remains on track for July 2019. Through the execution
of this share buyback program, the Group reaffirms its confidence in the strengths of its
underlying fundamentals, excellent ratings and optimal debt leverage.
Let me now hand over to Mark for the financial detail. Mark, the floor is yours.

Mark Kociancic

{BIO 17852409 <GO>}

Thank you, Denis, and good morning, everyone. So let's begin on slide four. I'll walk you
through the financial highlights of the first half of 2018's results. SCOR underwrote just
above EUR7.5 billion of gross written premium in the first half of the year, representing an
8.2% increase over the first half of 2017 at constant exchange rates or 0.2% at current
exchange rates.

Bloomberg Transcript

This top-line growth was fuelled by the strong contribution of both business engines,
SCOR Global P&C with a 4.9% growth at constant FX, and SCOR Global Life with a 10.5%
rise at constant foreign exchange. P&C net combined ratio for the first six months of the
year stands at 91.4% for the 2.3% nat cat ratio.
The normalized net combined ratio stands at 95.1%. And this is in line with the
assumptions of Vision in Action. The Life technical margin reached 6.9%, also in line with
Vision in Action. And finally, SCOR Global Investments delivered a good return on invested
assets at 2.5%. Overall, SCOR's net income for Q2 2018 stands at 262 million with an ROE
of 8.8%. If we exclude the US tax reform charge of 75 million or EUR62 million, the net
income would stand at 324 million.
And this translates into a normalized ROE of 10.9% above the Vision in Action target of
800 bps over the five year risk-free-rate. SCOR's solvency position remains strong at
221% at the end of Q2, marginally above the optimal range of our solvency scale.
Going to page six, shareholders' equity stood at the end of June at EUR6 billion,
compared to the 2017 reduction mainly comes from the currency translation adjustment,
primarily due to the strengthening of the US dollar at the beginning of the year, and from
the 312 million dividend payment in Q2. This translates into a book value per share of
32.08 at the end of June.
Our financial leverage stands at 28.4%, temporarily above the Vision in Action assumption
of 25%. And we expect this to come back to within our range, after we call our Swiss debt
this November and as net income is earned in future quarters.

Page 3 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

Moving to page seven, SCOR generated operating cash flows of 253 million. SCOR
Global Life benefits from strong cash flow. While SCOR Global P&C, the operating cash
flow reflects the claims payment impact from the 2017 nat cat events. And without the
exceptional HIMM payments, the operating cash flow would have been at approximately
EUR450 million for the first half of the year. Overall, the total liquidity of the group is
strong and stood at EUR1.2 billion at June 30.
Let me now hand it over to Victor, who will give you more details on the P&C results.

Victor Peignet

{BIO 6287211 <GO>}

Good morning. This quarter has been pretty much eventless, and my comment will,
therefore, be short. Growth for the first -- the second quarter and the first semester of
the year, all the KPI [Technical Difficulty] with the net combined ratio of 91.1% for the
quarter and of 91.4% on the year-to-date basis. Technical result is good and in line with
the indication we gave at the end of Q1.

Bloomberg Transcript

Once normalized, the year-to-date net combined ratio of 95.1% confirms the quality of the
book of business and the efficiency of its active management. It's at the upper end of the
94% to 95% range because over here, heavier than normal load from large manmade
losses in the second quarter. We don't see any particular pattern in the number of large
manmade losses that have occurred in this quarter whether it be by nature, by goals, by
sector or by geography.
In parallel to the good technical performance, the year-to-date growth at constant
exchange rates that are shown on the two slides of respectively 4.9% on an accountingyear basis, and of 7.8% on an underwriting-year basis for the renewals confirm our ability
to manage our client relationship and to continue to progress in the current market.
The media renewals show a continuation of the positive pricing trend albeit at the slightly
lower rate of increase of 2.3% versus the 2.9% recorded since the beginning of the year.
To give you a basis of comparison, I would say that for the technical ratio, the pricing of
the portfolio as a whole is now back close to the level of 2014 and for the return on risk
adjusted capital at the level of 2015. We expect the growth over the entire year to be in
the upper half of 3% to 8% range that we have assumed in Vision in Action.
On this, I hand over to Paolo for his comments on Life.

Paolo De Martin

{BIO 15930577 <GO>}

Thank you, Victor. SCOR Global Life had an excellent first half in 2018, where we continued
to deliver strong performance both in terms of profitability and franchise. In the first six
months of 2018, gross written premiums have reached EUR4.5 billion with an increase of
10.5% at constant exchange rate, or 2.5% at current exchange rate.
Once again the growth was well diversified, both in terms of geographies and product
lines. We have continued to deliver according to strategic plan Vision in Action, in
Page 4 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

particular, where -- with our Life & Health franchise expansion in Asia-Pacific and the
execution of new financial solution business. For the full year 2018, we expect premium
growth to normalize at around 6% in line with Vision in Action annual premium growth
assumption. The technical performance with the first half of 2018 remains robust with an
increase in net technical result of 9.7% and technical margin at 7% both at constant
exchange rate.
The profitability benefits from both the profit of growth of new business as well as the
strong performance of the in-force portfolio with US mortality development in line with
your expectations. As Denis said, I would like to also report that we successfully launched
the SCOR Life and Health Ventures, that is accelerating our innovation strategy.
I'll now hand over to Francois for more details on the group investment strategy.

Francois de Varenne

{BIO 7447858 <GO>}

Bloomberg Transcript

Thank you, Paolo. Moving on to slide 11, SCOR's total investments portfolio reaches
EUR27.3 billion at the end of June, with an invested asset portfolio of 19 billion compared
to 18.9 billion at the end of March. The positioning of the investment portfolio is in line with
the Vision in Action target asset allocation. Liquidity is stable at five points of the invested
assets in line with the target level defined for the strategic plan.
The share of corporate bonds in the invested asset portfolio has been again increased by
two points compared to the previous quarter and reaches 49% close to the maximum of
50% defined for the plan, and a duration of the fixed income portfolio is unchanged at 4.6
years.
Our fixed income portfolio remains a very high quality, with an average rating of A+, and
highly liquid. Indeed, at the end of June, expected financial cash flows from the fixed
income portfolio over the next 24 months stands at 5.1 billion, allowing SCOR to benefit
from increasing our investment rates.
SCOR Global Investments delivered a 2.5% return on invested assets for the first
semester, which is supported by your continuing increase in the income yield at 2.0% in
2016, 2.1% in 2017, and now 2.3% during the first half of 2018. We benefit from the
continuing improved reinvestment yield of 2.8% at the end of June.
Under current market condition, we expect the annualized return on invested assets to be
in the upper part of the Vision in Action 2.5% to 3.2% range, both for 2018 and over the
entire strategic plan. This level could be achieved, thanks to the disposal of a significant
equity co-investment that might be completed in the later part of the year.
With this, I will hand it over to Ian Kelly for the conclusion of this presentation.

Ian Kelly

{BIO 19976646 <GO>}

Page 5 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

Thank you, Francois. On page 12, you will find the next scheduled events starting on
September the 5th with our Investor Day here in Paris as well as the upcoming
conferences, which we are planning to attend during 2018.

FINAL

With this, we can start the Q&A session. Thank you.

Questions And Answers
Operator
Thank you. (Operator Instructions) Our first question today comes from Guilhem Horvath
of Exane. Please go ahead. Your line is open.

Q - Guilhem Horvath

{BIO 18460437 <GO>}

Bloomberg Transcript

Yes, thank you. Good morning, everyone. My first question is for Victor. I'd like to know a
little bit more on these manmade losses. Can you discuss a little bit what they are, how
much they represent in terms of both of -- in euro terms and in terms of combined ratio
points for the quarter? And the second question is for Francois, regarding the running
yields. So you have an improvement there. Obviously, I guess, the Q2 running yields
contains a little bit of dividends coming from your holdings. Can you break this down
please in terms of what is the underlying running yield and what comes from Q2
dividends?
And then, what could be the full year running yield and the contribution from realized
gains within this target that you reiterate today? And also, if you can discuss what is the
actual reinvestments yield because you report 2.8%, but I guess this is at constant
portfolio mix, but you're not reinvesting at the same at least currency mix as the one you
had at the end of quarter? Thank you.

A - Denis Kessler

{BIO 1498477 <GO>}

Victor, the manmade losses, claims...

A - Victor Peignet

{BIO 6287211 <GO>}

Well, first of all, it's not the first time that we have a quarter that is a bit heavy on
manmade, that's the case. And then, on the year to date basis, you should integrate the
fact that we are perfectly at normal. So it means that the normality of the quarter is
already basically spread. And back to a more normal on two quarters. So I think we should
not give it too much your attention.
Regarding the losses, well, they are geographically very spread, from Greece to US. They
are by nature and by industry sector was different. The higher one is contingent business
interruption loss that affects a car manufacturer following a fire in one of the supplier
plant. I think on that I would only comment that we have a pretty tight control on our
contingent business interruption exposures, which means that what we are been able to
reserve for that loss is based on sub-limits of the policies and exhaustion of the sub-limits,

Page 6 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

we are pretty much safe on the reserving, even though the loss itself is dated back to
May and is far, far from being adjusted.

FINAL

So once again, I mean, nothing, no trend, no pattern, while something that we have
already balanced over two quarters, so nothing really to worry about in my opinion.

Q - Guilhem Horvath

{BIO 18460437 <GO>}

In terms of amounts, total amounts?

A - Victor Peignet

{BIO 6287211 <GO>}

About EUR150 million net, in total.

Q - Guilhem Horvath

{BIO 18460437 <GO>}

Thank you.

A - Francois de Varenne

{BIO 7447858 <GO>}

Bloomberg Transcript

So on your question, the first one on the income yield or recurring yield, so the pickup this
quarter and the income yield is due to the very favorable condition, at which we managed
to reinvest since a few quarter notably in the corporate bond space and more particularly
in the US space, as well as higher allocation to higher-yielding assets places [ph].
However, the 2.4% observed [ph] in Q2 benefit from some non-recurring item. The
underlying recurring income yield stands at 2.3% for the quarter, so we have 10 basis
points of one-off in Q2 due to seasonality.
For the full year 2018, the income yield should be in the 2.2%, 2.3% range with a high
probability to be in the upper part of this range. So as mentioned, the recurring yield has
been gradually and progressively improving since 2016, benefiting from improved
investment condition. The reinvestment rate is at 2.8% for this quarter. We have a strong
appreciation of the reinvestment yield in dollar. Not yet in euro, but that should come in
the second part of 2019 with the expected increase of interest rate by ECB.
Just to note on the definition of the reinvestment yield, the reinvestment yield is the
market yield of the fixed income portfolio at the end of the quarter. So on the quarter, we
benefitted from an improvement, of course, in the yield curve, but also on credit spread,
which is positive for the portfolio.

Q - Guilhem Horvath

{BIO 18460437 <GO>}

Okay, thank you.

Operator
Thank you. Our next questions now come from Vinit Malhotra of Mediobanca. Please go
ahead. Your line is open.

Page 7 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

Q - Vinit Malhotra

{BIO 16184491 <GO>}

FINAL

Good morning. So my main topic would be just on the larger picture on the hurricane
losses, because it seems that, that's what is attributing to some of the Florida pricing
disappointment. You've taken only, I understand, maybe EUR17 million net release from
hurricane. But how much do you think the market is different from the magic $100 million
number we saw last year, that -- or heard last year, so that's my main question really.
Thank you.

A - Denis Kessler

{BIO 1498477 <GO>}

So question to (inaudible).

A - Victor Peignet

{BIO 6287211 <GO>}

Bloomberg Transcript

I understand your question in view of some of the revisions that are going on. But, I mean,
ourselves we have always said that it was around EUR95 million, did not change. What I'd
like to insist on is that we set our reserves in Q3 last year. We've not moved since then,
we are just starting to see some improvement, and we're just -- as you rightly say, we're
adjusting by bit less than 20 million down.
And we still have quite a bit of a buffer on the reserve. So even though, we are not at the
end of the process, we are quite portable with the level of reserves that we have set
from the beginning and have not changed. So I think that, personally, I think that it may be
a bit lower than the 95 million, but I think at the end, the original estimates we're probably
correct. And I think there were a lot of comments regarding late developments, possible
late developments in this year and the current of this year. I think we had anticipated that
very well. And I feel we are in a good position on that one.

Q - Vinit Malhotra

{BIO 16184491 <GO>}

Can I just follow-up on the previous question, please? You've mentioned a number of
manmade losses for 2Q of 150 million, just to be -- just to check that number, please.

A - Victor Peignet

{BIO 6287211 <GO>}

You want me to be fully naked? 142...

Q - Vinit Malhotra

{BIO 16184491 <GO>}

No, no, no, just want to -- just -- no, but okay, because I understood from IR that it is of the
(inaudible) because 142 is a very large number.

A - Victor Peignet

{BIO 6287211 <GO>}

Oh, you asked, I mean, (inaudible)

Q - Vinit Malhotra

{BIO 16184491 <GO>}

Wow, okay. That's a very big number, okay.

Page 8 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

A - Victor Peignet

{BIO 6287211 <GO>}

It is bigger than usual, it's what we said. But if you average over the first six months of the
year, we are back to normal already. So it is not -- which is why I'm saying it's not worrying.

Q - Vinit Malhotra

{BIO 16184491 <GO>}

FINAL

All right, fair enough. Thank you very much.

Operator
Thank you. Our next question comes from Sami Taipalus of Goldman Sachs. Please go
ahead. Your line is open.

Q - Sami Taipalus

{BIO 17452234 <GO>}

Hi, everyone. Can I just start with a question on the capital management? You've obviously
bought back about 40 million or so of shares in the quarter. And you also -- the debt you
issued I think was about 50 million or so higher than or will increase -- lead to roughly 50
million net increase in outstanding debt of the year once you include the cost that you
plan to make. I mean, both of these actions kind of increased your debt leverage.

Bloomberg Transcript

And I'm wondering why you're choosing to take this action, given that you are already
above your target debt leverage. Is there any particular -- anything in particular you need
the money for? Wouldn't it have made more sense to use your capital to reduce debt
leverage instead? So I don't know if you want to start by answering that one and I've got
another one on operational stuff later on.

A - Denis Kessler

{BIO 1498477 <GO>}

You can hop by this question.

A - Victor Peignet

{BIO 6287211 <GO>}

Yeah, sure. Our debt leverage ceiling assumption in Vision in Action is 25%. That's
something that we were meeting at the early stage of Vision in Action. Last year, in 2017
we experienced a significant decrease in the currency translation adjustment aspect of
our shareholders' equity because of the US dollar vis-a-vis the euro. And mechanically,
that has some impact on increasing the debt leverage. We're not concerned at all with
where we are with the debt leverage, right now.
Mechanically, it would have reduced to 26.6%, because we refinanced a callable bond,
Swiss debt bond from this November. We redeemed one is June as well. So I think you'll
see us naturally reduce backend line with that 25% figure over time. And it's more a
function of adding retained earnings to the shareholders' equity position. Share buyback
was something we announced last year, we're still very comfortable with it. And we
execute that independently of its impact on the debt leverage ratio, it's not a concern, it's
not an issue. Not an issue, that's been raised by rating agencies or other stakeholders.

Page 9 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

Q - Sami Taipalus

{BIO 17452234 <GO>}

FINAL

Yeah. Look, I guess, the reason I am asking is, you're above the range that you've
communicated, I guess, that could potentially constraint on what you can do during the
rest of the year. It's obviously a number that subject to some volatility based on what
currency and interest rates are doing?
So wouldn't it more -- be more prudent to operate sort of lower down in the range, and
you could have actually delivered the EPS accretion by reducing your net outstanding debt
anyway rather than via the means of buyback? So I mean, it's a figure that you've
communicated to debt holders and rating agencies. I am wondering, why you're taking it
so vitally to move above the target range?

A - Victor Peignet

{BIO 6287211 <GO>}

Well, I think going above the target range is mechanical effect. It wasn't our ambition to
get to 28% or 26%. We've like I said the core earnings of the group are quite strong, the
rating capital position is quite strong, so these are independent positions. We took the
opportunity over the last three debt issuances in particular to execute long-term debt
issuances with 11, 12 year type maturities before the first fall to secure the long-term
financing of the company, of the group over a significant period of time. So that is a
significant benefit to the group. And it's definitely, what I would call more long-term focus
and short-term focus of just managing our quarterly debt leverage ratio and few basis
points on the ROE.

Bloomberg Transcript

Q - Sami Taipalus

{BIO 17452234 <GO>}

Okay. And then my second question -- sorry, did you want to add anything to that? My
second question is -- yeah, sorry, go ahead, go ahead.

A - Mark Kociancic

{BIO 17852409 <GO>}

I'll just finish with one point, sorry, Sami.

Q - Sami Taipalus

{BIO 17452234 <GO>}

Yeah, no worries.

A - Mark Kociancic

{BIO 17852409 <GO>}

Terms and conditions on the debts that we issued were exceptional. We've been able to
dramatically lower the cost -- average cost of our outstanding debt by almost 200 basis
points since the last plan. And our issuance more recently, the Tier 1 that we had back in
March was an exceptional trade especially for initiating Tier 1 market. So I think, we're
locking in superior terms that are going to provide long-term shareholder value ultimately.

Q - Sami Taipalus

{BIO 17452234 <GO>}

Yeah, I mean, I think, if you compare it to other issuances by normalized companies in the
quarter. It's -- the interest rate was actually a bit higher. But nonetheless moving on to my
second question, which was on the underlying combined ratio. Just, I mean, we had a
Page 10 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

couple of quarters now -- or normalized combined ratio. So we had a couple of quarters,
where this is balanced around a bit, so it was quite lower in Q4, quite lower in Q1, and
then a bit higher now.
I guess what I'm wondering is, when you look at the pricing you're getting in the market. Is
there any reason for you to change the outlook you have on the normalized combined
ratio? Or is what you are seeing consistent with the existing guidance that you have out
there. I guess, the way I am thinking about this, is that, yes, we've seen pricing improved a
little bit this year, but that's -- but the target we set a couple of years ago. And if we look
ahead, it might be prudent to assume that maybe pricing will -- we might see some
pressure next year, assuming normal loss activity. So I'm just wondering, how you guys
think about this.

A - Mark Kociancic

{BIO 17852409 <GO>}

We've been -- as you said, trending quite stably between 94.5 to 95. I don't see why we
should change that, I think, we are safe around that tranche with the sort of business
development we see, with the sort of pricing, we are able to negotiate. Portfolio
management in addition of that, I think, we're okay for the moment. And I'm still hoping
that the prices are going to stem.

Q - Sami Taipalus

{BIO 17452234 <GO>}

Okay, great. Thanks very much for your answers.

Bloomberg Transcript

A - Mark Kociancic

{BIO 17852409 <GO>}

I think -- think there is, in my opinion, there is -- there are different trends in the market
today, I mean, it's obvious that the -- there is increase of the total reinsurance premium.
The available premium is increasing. But basically, that increase is coming much more from
large companies buying more and small companies buying less. So there is a
management of portfolio that has got to be done. And there is, in my opinion, today, an
advantage to larger size companies, larger size reinsurers with the diversification, with the
ability to trade with large clients. And I think there is definitely an advantage in portfolio
management through that category of reinsurers, to which we belong.

Q - Sami Taipalus

{BIO 17452234 <GO>}

So we should be more focused on the sort of top line opportunity here rather than the
margin opportunity, I guess, is what you're saying from your perspective?

A - Mark Kociancic

{BIO 17852409 <GO>}

I think we have always said that our goal is to maximize top line under constraints and
that's exactly what we're doing. We are pricing the business on a very disciplined way. We
are managing the portfolio, but if we can get more top line within the target, which is both
basically underwriting ratio, technical ratio and return on capital. Yeah, we'll definitely do it.
And that's what we've been doing over the years.

Q - Sami Taipalus

{BIO 17452234 <GO>}
Page 11 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

Okay, great. Thanks very much for your answers.

Operator

FINAL

Thank you. Our next questions now come from Andrew Ritchie of Autonomous. Please go
ahead. Your line is open.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Hi, there. I have a question for Paolo, who's been very quite. Paolo could you just give me
an update on the claims experience in the US? I'm thinking particularly on some of the
older age blocks, your revised assumptions on at least in S2 terms last year. How the
experience been year-to-date? How sort of winter washed out in terms of what you're
hearing from your cedants? Just a bit more color on that would be useful?
Secondly, could we get a sense as to what drivers were of S2 in the quarter between
market movements and operating capital generation? And obviously, we know the
buyback and dividend accrual was? Thanks.

Bloomberg Transcript

A - Paolo De Martin

{BIO 15930577 <GO>}

So on the first question, Andrew. On the US mortality, the first six months of the year were
in line with the expectations that we had. So there's really nothing to report, relatively
uneventful. The seasonal flu of 2017, we expect that to be higher than the usual flu. We
also believe there will be offset by overall strong performance of the in-force book. So
that will flash through our books in Q3 and just a little bit in Q4. But we believe that will be
offset by the rest of the performance of the book.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

And as the -- when you say it's been in line with assumptions, in line with the revised
opposite assumptions has a normalize backed down again in the claims experience?

A - Paolo De Martin

{BIO 15930577 <GO>}

Correct. In line with the revised assumption.

A - Denis Kessler

{BIO 1498477 <GO>}

You want to add something, Andrew?

Q - Andrew Ritchie

{BIO 18731996 <GO>}

On Solvency II -- yeah, sorry, the evolution of Solvency II.

A - Unidentified Speaker
(inaudible)

Page 12 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

So there are no unusual movements in this solvency ratio in Q2, a very slight reduction
because of economic movements, but small. As in previous quarters, we've reflected the
shares, which we have repurchased in Q2. So that is a reduction obviously in addition to
the accrual of the dividend. And that's been broadly offset by strong capital generation
from the business, largely in line with what we would have seen in previous quarters.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Well, this capital generation almost equally offset by a combination of the accruals of
capital plus market movements?

A - Unidentified Speaker
Yeah, you can look at in this way, yeah.

Q - Andrew Ritchie

{BIO 18731996 <GO>}

Okay. Thanks.

A - Denis Kessler

{BIO 1498477 <GO>}

Andrew, next question please.

Operator

Bloomberg Transcript

Thank you. Our next question today comes from Kamran Hossain of RBC. Please go
ahead. Your line is open.

Q - Kamran Hossain

{BIO 17666412 <GO>}

Hi, good morning. Thanks for taking my questions. Just two. First one and apologies if I
missed it. Just on the improvement in the HIMM losses. Was there one in particular
improved better -- or kind of move -- did all improve or was there one in particular, the
improved kind of the way, I understand it's that Harvey has improved quite a bit?
And the second question is, just on the underlying of the normalized combined ratio and
casualty. Are you seeing any more signs of encouragement that you might begin to
increase your business in casualty? Thank you.

A - Victor Peignet

{BIO 6287211 <GO>}

Okay. While on the cat it's relatively marginal improvement, 20 million out of total net of -in dollars something like $770 [ph]. So I think for the moment what we are seeing is -- is
positive, of course. But it's still early. What is important for me is the sort of buffer that we
carry on top of information, we have received from ceding companies and the level of
comfort we have in the reserve. Then we will see over time of how it goes. But very
comfortable with what we booked.
Regarding the casualty in the US. Well, we are just continuing as we have done over the
last two to three years. We are building up the portfolio block by block. I mean, we see
Page 13 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

the business, we evaluated, we have not return as much as we could have written. In
order to basically keep the overall underwriting ratio and return on capital and within the
plan for -- and for the division. So nothing -- our casualty book in the US at the moment
has reached about dollars.
So we are on kind of a distribution like 65 properties, 35 casualty. We are still having some
room to improve the balance. But we will -- we'll continue to do that as market conditions
permit. But there are signs of primary rates evolving in the right direction. So we would
see. But we are also quite cognizance of loss trends and we definitely want price to
improve above just matching the loss trends.

Q - Kamran Hossain

{BIO 17666412 <GO>}

That's right. I appreciate the color, Victor.

Operator
Thank you. Our next question comes from Ivan Bokhmat of Barclays. Please go ahead.
Your line is open.

Bloomberg Transcript

Q - Ivan Bokhmat

{BIO 15378004 <GO>}

Hi, good morning. Thanks for taking my questions. First of all, maybe a bigger topic on the
next 12 months. Do you see, do you think that the reinsurance rates are close to have
being bottomed or rather the improvement have been done for this year and what would
you expect for 2019, maybe if you could spot any divergence by regions that would help.
And secondly, it's more of an operating question I've noticed you've been doing some
restructuring in the core business solutions. And then your London market business,
maybe you could expand a little bit on that. What impact on business, should we expect.
Thanks.

A - Victor Peignet

{BIO 6287211 <GO>}

I'll address the first one and Laurent will address the second. Both of them are a bit linked
and I don't understand really this sort of pessimism that you seem to be willing to put on
the business. I mean, we are not pessimistic. I mean, we are delivering. We have been
delivering. I mean lot of people would dream about a net combined ratio of 91% for a
global diversified reinsurer.
So I mean, you seem to be willing to by all means to have a saying that, well, you are
basically under pressure on price. No, the prices are improving. They are not improving at
the level they should in our opinion, but they are improving. And this current market stage,
we are delivering. So -- and we have relationship with clients, where we believe we are in
a position to negotiate. So I would myself will not enter and renewal session with this sort
of conviction that things are not good and are likely to deteriorate. Things are not bad and
they are likely to continue to improve moderately as they are unless something else
happens.

Page 14 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

So I don't share your view of pessimism. And in our operation, the reorganizations we are
doing is our -- reorganization not because we have problems, but we have because we
have ambitions. We want to continue profitable growth. So we are reorganizing our
operation in order to maximize business synergies and get more efficiency in the
business, produce more at the level of profit we are today or both. So Laurent, maybe
you want to talk about what is done with SBS and the London platform.

A - Laurent Rousseau

{BIO 5131107 <GO>}

Yes, let me add to that, essentially there are two announcements we did. The first one
mid-May on SCOR Business Solutions, which is our large commercial lines insurance and
fac [ph] business. It is a business we're in for like over 30 years, focusing on technical
heavy occupancies and taking a fairly technical approach.
This business has been performing pretty well, strong underwriting performance and
taking a very technical approach to energy, construction, and heavy occupancies. Our
ambition there, I guess, is two-fold. One is to broaden the product range and keeping
that technical approach. And two, is to continue to have an original approach and growth
in APAC, EMEA, and Americas, and combining these developments across through
regions and across a broader range of products.

Bloomberg Transcript

So that was an announcement in May and so far it's doing well. It's going to take us some
time. This is going to be a development plan for the next two years. The second
announcement was in 9th of July. And here with regards to our London market specialty
insurance business. What we call the London market specialty insurance is the
combination of channel, our Lloyd's Syndicate, which started operating in 2011.
And SCOR Business Solutions in London. The idea there is, as Victor mentioned is a
growth plan. There is no -- it's not a cost-cutting plan, it's not a negative plan, it's quite
contrary to that, is how can we bring the two platforms closer together and offer greater
value proposition to our clients in the London market.
The second point I'd like to make is, this announcement we made has actually started -has started being prepared last year. It has been long prepared. The CEO of the
Managing Agency has told us last year, that he would retire and we put in place a
succession plan and have hired a successor, who arrived at SCOR early April. And so, in a
way of this announcement is in the continuity, first of all of the channel syndicate strategy,
which has developed and with a strong infrastructure.
The second point is, the succession of David Reed the CEO of the Managing Agency was
well anticipated and he is staying as non-executive director of the Syndicate. Even though,
he's going to retire from his executive position, he would remain as a non-exec.
And third, I guess, the third point is this growth plans with SBS and having the ability to use
Lloyd's paper and company paper in a flexible way. So I think, it's important to have a look
at these announcements in a development way, and as well in a very logical way if you
look at it from a historical perspective and the long-term ambitions that we have.

Page 15 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

Q - Ivan Bokhmat

{BIO 15378004 <GO>}

Thanks. Just to clarify, I wasn't trying to bring down the moods, but obviously, the markets
color has been perhaps progressively deteriorating, whereas your results have indeed
kind of, bucked the trend. Thank you.

FINAL

A - Denis Kessler

{BIO 1498477 <GO>}

Thank you. Next question, please.

Operator
Thank you. Our next question comes from Vikram Gandhi of Societe Generale. Please go
ahead. Your line is open.

Q - Vikram Gandhi

{BIO 18019785 <GO>}

Hi, morning, everyone. Thank you for taking my questions. The first question is around the
Ogden rate. We still don't have any visibility around the new Ogden rate and considering
that there might be a potential delay in the announcement. Can you please comment on
how you plan to approach the reserving in the meantime?
And the second is, it will be great, if you can provide an update on where you are with the
merger of the three French entities? That's all from my side.

Bloomberg Transcript

A - Denis Kessler

{BIO 1498477 <GO>}

Thank you. Ogden rate, I said, we tackled the issue last time, but, Victor, maybe?

A - Victor Peignet

{BIO 6287211 <GO>}

No. We are not changing our position, we have reserved, we have anticipated in a way,
but in a very moderate way. We have decided to reserve at zero from September of this
year. We are -- that's what we're doing. But we don't know any more than you do
regarding where it's going to land and how it's going to land. But I mean, we feel that it's
going to land positive somewhere, which can only be good news for us. But for the
moment, we should -- we basically hold that at zero.

Q - Vikram Gandhi

{BIO 18019785 <GO>}

Okay. And on the merger of the French entities?

A - Mark Kociancic

{BIO 17852409 <GO>}

Yeah, on the three SEs, so this is another business, as usual, type update, we continue to
make progress on schedule, and we're targeting a January 1, 2019 implementation date -effective implementation date. The approval will likely come later in the first quarter, but
with a retroactive effect. So I expect it to be completed on schedule by the end of March.
And the benefits that we expect are roughly in line, we haven't done any serious update
on the risk margin update. But I gave guidance last year that was close to EUR200 million
of risk margin benefit from out of it.
Page 16 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

Q - Vikram Gandhi

{BIO 18019785 <GO>}

Okay. Thank you very much.

A - Denis Kessler

{BIO 1498477 <GO>}

FINAL

We're on track. Next question, please.

Operator
Thank you. Our next question comes from Frank Kopfinger of Deutsche Bank. Please go
ahead. Your line is open.

Q - Frank Kopfinger

{BIO 16342277 <GO>}

Bloomberg Transcript

Yes, good morning, everybody. I have two questions. My first question is on the tax effect.
So obviously, you remove now this one-off charge, where you should have a benefit now
going forward from lower US and French taxes. Can you comment on what we should -what and when we should expect to have an effect on this? And then secondly, on the
investments, one of the targets was also to match the duration and change this assetliability mismatch there. I was only wondering because what we saw now at least in the US,
is that there is a spread narrowing between short-term bonds, so let's say two years and
10 year bonds. And I was wondering whether there is even a requirement that you need
to change this asset gap given that you get almost the same yield on a duration bond
now?

A - Denis Kessler

{BIO 1498477 <GO>}

Mark, first on the benefits of the US tax reform.

A - Mark Kociancic

{BIO 17852409 <GO>}

Yeah. On the tax side. So I think the -- we've made this point before we do expect to
marginally positive benefit for our P&C operations globally as a result of the changes in
the US. I think the French rates will be an issue -- more of an issue or impact in 2020. And
then 2022 in the second reduction comes, so that's a little bit further out. In terms of the
Life side, we expect it to be broadly neutral in terms of the effective tax rate of the Life
division.
I do expect probably some frictional tax expense to remain in 2018 in terms of the second
half of the year from the beat impact in the US. And when I say frictional that would be
probably on the EUR5 million to EUR10 million range for the remainder of the year. I would
expect this to stay in the 22% to 24% range next year, probably at the lower end, and
potentially improving on that that figure, but it should diminish over time. Francois?

A - Denis Kessler

{BIO 1498477 <GO>}

On the duration to, that's true that we are almost matched today the duration I
mentioned of the fixed income portfolio is unchanged at 4.6 years during the quarter. And
that's true what you said, we did during Q2 kind of twist operation in the USD

Page 17 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

denominated portfolio. Just to give you an example on the corporate bond space. We
invested in Q1 at an average maturing of six years.

FINAL

And in Q2, we reduced a little bit this average maturity of the corporate bond by -- at four
years. So with the same remuneration, but we have reduced a little bit the maturity given
the flatness of the recovery [ph] in the US.

Q - Frank Kopfinger

{BIO 16342277 <GO>}

Okay, thanks.

A - Denis Kessler

{BIO 1498477 <GO>}

Next question, please.

Operator
Thank you. (Operator Instructions) Our next questions come from Jonny Urwin of UBS.
Please go ahead. Your line is open.

Q - Jonny Irwin

{BIO 20491581 <GO>}

Bloomberg Transcript

Hi, there. So first question, you mentioned technical pricing on the P&C book is back to
2014 levels. It seems like quite a good level given the excess capital in the industry. I
wondered if you had a view on where the market is at the moment in terms of technical
profitability? Are you a bit ahead of the market? That would be my first question.

A - Victor Peignet

{BIO 6287211 <GO>}

No. I can't really say that because I think we are having very precise figures and statistics
for our book. But for the entire market, our book is very different from an average of the
average book. So no, I can't give you an answer on that.

Q - Jonny Irwin

{BIO 20491581 <GO>}

All right. That's fine. I mean, it sort of leads into my second question, which is I mean, if
you are at 2014 levels and say in the market maybe 2015. I know, some companies
commented that they wanted to get back to 2015 levels after the Hurricanes, but they
said they didn't quite get there. But say, if the the market is sort of 2015 maybe 2016,
then if Hurricane season runs clean from here and capital build then I am struggling to
understand, why pricing wouldn't fall again, especially if the market is at 2015 levels of
profitability. Because, we've got much more capital since then, and I don't think demand
has risen terribly. So I'm just struggling conceptually to understand why pricing wouldn't
decline, if we had a -- have a clean Hurricane season? So any comments there would be
great.

A - Victor Peignet

{BIO 6287211 <GO>}

Well, I would say myself that you are looking at things through the prism of the US cat
business. I mean, US cat business is only part of the overall, and it's not driving the overall,
Page 18 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

and it's not even driving the US market as a whole. So I think this is an element of the total.
What I would say is, what has happened over the years, over the past years, there has
been an erosion of the superior profitability of the US cat business. I mean, that business
used to be priced higher, the return better.
So basically, people who had been relying enormously on US cat to produce the results,
well, of course, are seeing a bucket of superior margin business that is shrinking and that
is creating an issue. But if I take our case, we are in a completely different position, first of
all. I mean, we have never really enjoyed those periods of superior margins, because we
were not heavily involved in US cat at the time. And while we are building a book that is an
overall diversified book. So the impact of US pricing on the total, we can manage it in a
different way, because we don't come from the same position.
As far as the renewals are concerned, well, I think, negotiations are going to take place.
But again, I would say that when you're negotiating on a US cat only basis, that's one way. I
mean, our relationships with clients are global relationships across all their needs, all their
lines of business. So I think the discussions are different in essence, and I would hope that
this difference, in essence, is going to continue to the benefit of company like SCOR.

Q - Jonny Irwin

{BIO 20491581 <GO>}

Brilliant. Thanks so much.

Bloomberg Transcript

Operator
Thank you. Our next questions now come from Iain Pearce of Berenberg. Please go
ahead. Your line is open.

Q - Iain Pearce

{BIO 19522835 <GO>}

Hi, good morning, everyone. Two questions for me, if I could. Just on the commission and
the expense ratio in the P&C business. I'm just trying to understand what's caused those
to take up in the first half of this year? And if there's anything to do with the sort of
business mix and the structure of that business that's caused those increase and should
we expect those to be slightly higher going forward?
And then just second one on investments. And apologies, if I misheard, but just was there
something mentioned about potential disposal in H2 leading to something that would
increase investment performance? And if you could give a bit more detail on that, that
would be great. Thank you.

A - Victor Peignet

{BIO 6287211 <GO>}

Well, the trend on the expenses is no surprise basically, it has got two origins. One is the
development of our insurance business, which carries a higher expense rate than our
reinsurance business. So that's one element. The second element is the fact that we have
increased our rate position, in particular, proportional rate position at 1/1/2018.

Page 19 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

FINAL

So there is a mathematical effect, which is that, if you reduce the denominator slightly
more than it used to be ceding a bit more, your net earned premium lowers, while your
expense ratio gets a bit higher.
What is important to me is once you stacked the attritional, the cat, the commission and
the expense ratio. Well, we are still delivering excellent net combined. But the trend on
the expense was anticipated. And if you would go back to Vision in Action, you would see
that we are in the ballpark of Vision in Action.

A - Denis Kessler

{BIO 1498477 <GO>}

It's due to the change of business mix.

A - Victor Peignet

{BIO 6287211 <GO>}

So the realized gain, just as a reminder, so we took during the first six months, 28 million
of capital gain, 19 million in Q1, mostly on the equity portfolio and 9 million on the related
portfolio in Q2. At the end of June, we have 288 million of capital gain on equities and real
estate. And as indicated, we plan to realize a substantial capital gain on an equity coinvestment in the course of the second semester, more probably in Q4.

Q - Iain Pearce

{BIO 19522835 <GO>}

Okay, perfect. Thank you.

Bloomberg Transcript

A - Denis Kessler

{BIO 1498477 <GO>}

Next question, please.

Operator
Thank you. Our next question come from Paris Hadjiantonis of Credit Suisse. Please go
ahead. Your line is open.

Q - Paris Hadjiantonis

{BIO 19703051 <GO>}

Yes, hi. Good morning from my side as well. I have two questions. The first one is a very
general one. Victor has discussed the benefit that global reinsurance, diversified
reinsurance player like SCOR has in the current environment. And in the past, Denis has
been pointing to the tiering in the industry with Tier 1 players benefiting a lot more than
Tier 2 and Tier 3.
My question is that, is based on the fact that we haven't really seen any kind of major
consolidation even on the back of the large losses last year. And also on the back of the
price increases, which are probably not what the industry was expecting. So maybe you've
seen somebody, is still not a major consolidation among the two Tier 3 and Tier 2 players.
Do you think that this will be changing in the coming quarters? And is it at all based on
what we're going to see during the joint audit renewals. So that's question number one.

Page 20 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

The second question, much simpler, Francois, can you remind us what the impairment
rules are for fixed income? Thank you.

FINAL

A - Francois de Varenne

{BIO 7447858 <GO>}

So on the fixed income portfolio, the impairment rule is very simple. Under current IFRS
rules, we impair a security when we think we have an evidence of a default of a
restructuring of the debt. We don't impair due to volatility and interest rates or credit
spreads. Just when we think there is a default or a high probability of default on an insurer.

A - Denis Kessler

{BIO 1498477 <GO>}

Bloomberg Transcript

On your first question, I mean, I think the hypothesis at SCOR first expressed about the
tiering of the industry that was more than four, five years ago. That seems to be valid. I
mean, this hypothesis seems to be confirmed as our five Tier 1 players, it's a global rule.
We'll diversified between (inaudible) operating on the five continents, being nicely rated
with the AA level of rating. And as you've seen, they've not been implied in major M&A
activities over the last four years. So that's what we said four years ago and seems to be
proven.
The movements you mentioned are the Tier 2 and Tier 3 sphere, where you see some
acquisition and merger. But that was a Tier 1 space, so it's certainly our -- this means the
case for the last four years. So I don't want to talk about the future. But if I had to make a
prediction, I see it would be valid for the years to come. So in those words, the tiering
would go on. Access to large business, the capacity you need to put forward, the number
of business lines you have to offer to your clients, that's a trend. Economies of scale,
economies of scope, those are trends.
Fixed cost, due to regulation and compliance, it's a trend. So basic factors, explaining why
you have a tiering of the industry, all those factors still play a role. So I don't see as it's
going to disappear. So critical size matters, size, capacity and so and so, because that's
why I believe the hypothesis you put forward is still valid and should remain valid. Mark,
you want to add something?

A - Mark Kociancic

{BIO 17852409 <GO>}

That answer was pretty complete. I would emphasize the benefits of scaling with respect
to pricing power, economies of scale for absorbing cost, whether it's regulatory burden or
technological burdens that we have to face as an industry. And clearly, there will be a
larger move forwards. I think from a productivity point of view amongst the larger players,
putting even more pressure on the Tier 2 and Tier 3s to have this strategic question of
consolidation in their future.

A - Denis Kessler

{BIO 1498477 <GO>}

Yeah.

Q - Paris Hadjiantonis

{BIO 19703051 <GO>}

That's useful. Thank you.
Page 21 of 22



Company N ame: SCOR SE
Company Ticker: SCR FP Equity
Date: 2018-07-26

Operator
Thank you. That will now conclude today's question-and-answer session. I would now like
to hand the call back to Mr. Ian Kelly for any additional or closing remarks.

FINAL

A - Ian Kelly

{BIO 19976646 <GO>}

Thank you very much for attending this conference call. Can I remind you that we have the
roundtable session later this evening, starting at 5 PM UK time, 6 PM Europe. And in the
meantime, please do not hesitate to call us, should you require any further information.
Thanks a lot. Have a nice day.

Operator

Bloomberg Transcript

Thank you. That will now conclude today's conference call. Thank you for your participation
ladies and gentlemen. You may now disconnect.

This transcript may not be 100 percent accurate and may contain misspellings and other
inaccuracies. This transcript is provided "as is", without express or implied warranties of
any kind. Bloomberg retains all rights to this transcript and provides it solely for your
personal, non-commercial use. Bloomberg, its suppliers and third-party agents shall
have no liability for errors in this transcript or for lost profits, losses, or direct, indirect,
incidental, consequential, special or punitive damages in connection with the
furnishing, performance or use of such transcript. Neither the information nor any
opinion expressed in this transcript constitutes a solicitation of the purchase or sale of
securities or commodities. Any opinion expressed in the transcript does not necessarily
reflect the views of Bloomberg LP.  COPYRIGHT 2022, BLOOMBERG LP. All rights
reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Page 22 of 22

